We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+14.9%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$272M
AUM Growth
+$12.6M
Cap. Flow
-$13.6M
Cap. Flow %
-4.98%
Top 10 Hldgs %
27.33%
Holding
177
New
29
Increased
50
Reduced
55
Closed
31

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$4.13M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$2.18M
3
CLDX icon
Celldex Therapeutics
CLDX
+$2.07M
4
CLF icon
Cleveland-Cliffs
CLF
+$1.9M
5
FERG icon
Ferguson
FERG
+$1.82M

Top Sells

Rank Stock Value
1
ACI icon
Albertsons Companies
ACI
+$4.15M
2
SWTX
SpringWorks Therapeutics
SWTX
+$3.03M
3
GEV icon
GE Vernova
GEV
+$2.41M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$2.1M
5
BHC icon
Bausch Health
BHC
+$2.03M

Sector Composition

Rank Sector Weight
1 Healthcare 37.62%
2 Technology 22.09%
3 Industrials 8.52%
4 Financials 6.08%
5 Consumer Discretionary 5.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GPCR icon
51
Structure Therapeutics
GPCR
$3.82B
$1.8M 0.66%
86,621
+69,060
+393% +$1.52M
SNDK
52
Sandisk
SNDK
$181B
$1.8M 0.66%
+39,600
New +$1.51M
RYTM icon
53
Rhythm Pharmaceuticals
RYTM
$7.95B
$1.77M 0.65%
28,068
-6,971
-20% -$427K
HPE icon
54
Hewlett Packard
HPE
$72.4B
$1.76M 0.65%
86,200
-47,300
-35% -$793K
PTC icon
55
PTC
PTC
$16.4B
$1.74M 0.64%
10,122
+41
+0.4% +$6.61K
TLN
56
Talen Energy Corp
TLN
$16.4B
$1.72M 0.63%
5,900
-1,800
-23% -$427K
SYRE icon
57
Spyre Therapeutics
SYRE
$9.29B
$1.69M 0.62%
112,805
+17,646
+19% +$261K
ENTG icon
58
Entegris
ENTG
$22B
$1.69M 0.62%
+20,900
New +$1.59M
CSCO icon
59
Cisco
CSCO
$483B
$1.64M 0.6%
23,600
-8,600
-27% -$529K
PGR icon
60
Progressive
PGR
$124B
$1.57M 0.58%
5,900
+900
+18% +$247K
BAC icon
61
Bank of America
BAC
$447B
$1.54M 0.57%
+32,600
New +$1.37M
DAL icon
62
Delta Air Lines
DAL
$58.7B
$1.51M 0.56%
30,800
– –
ALKS icon
63
Alkermes
ALKS
$8.29B
$1.51M 0.56%
52,944
-17,818
-25% -$530K
LQDA icon
64
Liquidia Corp
LQDA
$8.1B
$1.5M 0.55%
120,641
-82,869
-41% -$1.23M
APLS
65
DELISTED
Apellis Pharmaceuticals
APLS
$1.5M 0.55%
86,663
-22,051
-20% -$408K
SCHW
66
Charles Schwab
SCHW
$187B
$1.49M 0.55%
+16,300
New +$1.36M
GH icon
67
Guardant Health
GH
$22.4B
$1.47M 0.54%
28,265
-23,453
-45% -$1.05M
WDAY icon
68
Workday
WDAY
$45.5B
$1.46M 0.54%
6,100
+500
+9% +$122K
JANX icon
69
Janux Therapeutics
JANX
$1B
$1.44M 0.53%
62,436
-12,120
-16% -$319K
RCL icon
70
Royal Caribbean
RCL
$82.4B
$1.44M 0.53%
4,600
-4,200
-48% -$1M
CME icon
71
CME Group
CME
$94.8B
$1.43M 0.53%
+5,200
New +$1.41M
SE icon
72
Sea Limited
SE
$70.3B
$1.43M 0.53%
8,941
-1,700
-16% -$246K
XENE icon
73
Xenon Pharmaceuticals
XENE
$6.21B
$1.43M 0.52%
45,620
-21,168
-32% -$690K
RBC icon
74
RBC Bearings
RBC
$17.6B
$1.42M 0.52%
3,700
+300
+9% +$106K
TKO icon
75
TKO Group
TKO
$13.8B
$1.38M 0.51%
7,600
-1,600
-17% -$257K
1 2
3
4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

HighVista Strategies's Q2 2025 Portfolio in Review

As of Q2 2025, HighVista Strategies held 177 positions worth $272M, up 4.9% from $260M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

HighVista Strategies withdrew a net $13.6M in Q2 2025, closing 31 positions and reducing 55 holdings. Its most notable exit was Albertsons Companies, an estimated $4.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Mineralys Therapeutics worth $2.03M.

  • HighVista Strategies's largest Q2 2025 buy was Mineralys Therapeutics: 150,138 shares worth $2.03M.
  • HighVista Strategies added most to Viridian Therapeutics in Q2 2025, an estimated $4.13M increase.
  • HighVista Strategies's biggest Q2 2025 reduction was GE Vernova, cutting an estimated $2.41M.
  • HighVista Strategies fully exited Albertsons Companies in Q2 2025, selling an estimated $4.15M.
  • HighVista Strategies's ten largest holdings make up 27% of its $272M portfolio in Q2 2025.
  • HighVista Strategies opened 29 new positions and closed 31 in Q2 2025.
  • HighVista Strategies's portfolio value rose 4.9% quarter-over-quarter to $272M.

Based on HighVista Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.